335 related articles for article (PubMed ID: 16035256)
1. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
[TBL] [Abstract][Full Text] [Related]
2. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
3. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
[TBL] [Abstract][Full Text] [Related]
4. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
[TBL] [Abstract][Full Text] [Related]
5. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
10. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
[TBL] [Abstract][Full Text] [Related]
12. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
13. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
15. [Viral resistance and genetic barrier of atazanavir].
Mendoza CD; Garrido C; Treviño A; Anta L; Poveda E; Soriano V
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():28-33. PubMed ID: 20116614
[TBL] [Abstract][Full Text] [Related]
16. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
17. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
19. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of atazanavir in rescue therapy].
Portilla J; Boix V; Merino E; Reus S
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():22-7. PubMed ID: 20116613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
